Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients
Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Between January 2020 and January 2023, among 3847 patients consecutively hospitalized for COVID19, 57 (=UDCA group) were taking UDCA. The UDCA and the control groups (n = 3790) did not differ concerning comorbidities including diabetes mellitus type 2 (15.8% vs. 12.8%) and neoplasia (12.3% vs. 9.4%). Liver diseases and vaccination rate were more common in the UDCA group (14.0% vs. 2.5% and 54.4% vs. 30.2%, respectively). Overall mortality and CPAP treatment were 22.8 % and 15.7% in the UDCA, and 21.3% and 25.9% in the control group. Mortality was similar (p = 0.243), whereas UDCA was associated with a lower rate of CPAP treatment (OR = 0.76, p < 0.05). Treatment with UDCA was not an independent predictor of survival in patients hospitalized for COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Viruses - 15(2023), 8 vom: 14. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Colapietro, Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
724L30Y2QR |
|---|
| Anmerkungen: |
Date Completed 28.08.2023 Date Revised 07.09.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v15081738 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361302606 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361302606 | ||
| 003 | DE-627 | ||
| 005 | 20231226084843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v15081738 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361302606 | ||
| 035 | |a (NLM)37632080 | ||
| 035 | |a (PII)1738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Colapietro, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.08.2023 | ||
| 500 | |a Date Revised 07.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Between January 2020 and January 2023, among 3847 patients consecutively hospitalized for COVID19, 57 (=UDCA group) were taking UDCA. The UDCA and the control groups (n = 3790) did not differ concerning comorbidities including diabetes mellitus type 2 (15.8% vs. 12.8%) and neoplasia (12.3% vs. 9.4%). Liver diseases and vaccination rate were more common in the UDCA group (14.0% vs. 2.5% and 54.4% vs. 30.2%, respectively). Overall mortality and CPAP treatment were 22.8 % and 15.7% in the UDCA, and 21.3% and 25.9% in the control group. Mortality was similar (p = 0.243), whereas UDCA was associated with a lower rate of CPAP treatment (OR = 0.76, p < 0.05). Treatment with UDCA was not an independent predictor of survival in patients hospitalized for COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a UDCA | |
| 650 | 7 | |a Ursodeoxycholic Acid |2 NLM | |
| 650 | 7 | |a 724L30Y2QR |2 NLM | |
| 700 | 1 | |a Angelotti, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Masetti, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Shiffer, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a De Nicola, Stella |e verfasserin |4 aut | |
| 700 | 1 | |a Carella, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Ormas, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Calatroni, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Omodei, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccarelli, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Aliberti, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Reggiani, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Bartoletti, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Cecconi, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Lleo, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Aghemo, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Voza, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 15(2023), 8 vom: 14. Aug. |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:8 |g day:14 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v15081738 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 8 |b 14 |c 08 | ||